Since reduced concentrations of selenium in whole blood, plasma and white cells had previously been observed in psoriasis, 69 patients were supplemented daily with either 600 J.Lg of selenium-enriched yeast, 600 J.Lg of selenium-enriched yeast plus 600 IU of vitamin E or a placebo for 12 weeks. Before supplementation, the patients' mean concentrations of selenium in whole blood and plasma were reduced compared with those of matched healthy controls but their red cell glutathione peroxidase (GSH-Px) activity was normal. After 12 weeks supplementation the patients' mean whole blood, plasma and platelet selenium concentrations, platelet GSH-Px activity and plasma vitamin E concentration had risen significantly from the baseline values but their mean skin selenium concentration and red cell GSH-Px activity remained unchanged. The mean white cell selenium concentration rose only in the group receiving selenium alone. Neither supplementation regimen reduced the severity of psoriasis or produced side-effects.
Selenium is an essential trace element and the recommended intake for man is 50-200 J.Lg per day.' The average British diet contains 60 J.Lg of selenium per day with half derived from cereals and cereal products, and another 40% from meat and fish.' Selenium is well absorbed and in normal circumstances 55-60% is excreted in urine and most of the rest in faeces. Selenite, selenate and selenoaminoacids can all be converted into selenide.' Selenium deficiency reduces the activity of the selenium-dependent enzyme glutathione peroxidase (GSH-Px) (EC 1.11.1.9).4 A reduction in GSH-Px activity can lead to an accumulation of hydroxyl radicals.' The adverse effects of selenium deficiency can be lessened by vitamin E. 6 Psoriasis is an inflammatory skin disease. Reduced whole blood, plasma and white cell selenium concentrations? and reduced red cell GSH-Px activity" have been found in patients with psoriasis but the cause has not been deter-Correspondence: Dr G M Fairris.
mined." Oxygen radicals are intricately involved in the pathogenesis of ultraviolet light-induced inflammation'? which can be suppressed by supplementation with pharmacological doses ofselenium." These observations, along with the finding of a three-fold rise in free oxygen radicals in plaques of psoriasis, 12 suggested that supplementation with large doses of selenium might improve psoriasis by increasing selenium status.
In this study the effect of supplementation with selenium and vitamin E on psoriasis has been determined in a double-blind, placebo controlled trial. The study was approved by the Joint Ethical Sub-Committee of the Southampton and South West Hampshire Health Authority and the Faculty of Medicine of Southampton University and the DHSS Licensing Authority was informed.
Method
Sixty-nine patients with moderate or severe chronic stable plaque psoriasis, aged between 18 and The study was carried out double-blind and was designed to detect a 50% or greater improvement in psoriasis. During the study the patients' samples were identified by a study number alone and a sealed copy of the study code was kept in the pharmacy of both the general hospitals in Southampton, in case of emergency. The patients were allowed to apply selenium-free emollients to their skin during supplementation, but were excluded if they took vitamins or treated their psoriasis with tar or dithranol.
The supplements were taken each morning with food for 12 weeks. The patients were followed up 2, 4, 8 and 12 weeks after supplementation commenced and again 12 weeks after supplementation ceased. On each occasion, the PASI score was determined, symptoms which might be related to selenium toxicity were sought by direct questioning (garlic breath, nausea, vomiting, loss of nails and alopecia) and blood was taken to assess selenium status. As a precaution, haemoglobin, white cell count, platelet count and plasma urea, creatinine, alkaline phosphatase and aspartate transaminase were determined in the Departments of Haematology and Chemical Pathology at Southampton General Hospital.
To minimise discomfort, the skin biopsy was not repeated until the end of week 12 and the extra 15 mL of blood required to measure the concentration of selenium in white cells was only taken at the end of weeks 12 and 24. The second sample of skin was excised from an uninvolved The selenium status of each patient and control subject was determined by measuring the concentration of selenium in their whole blood and plasma and the activity of GSH-Px in their red cells. The differences between the measurements in the patients and controls were analysed using the paired Student's r-test, Further baseline measurements were then made in each patient. The severity of their skin disease was measured using the psoriasis area and severity index (PASI score)!' and venous blood was taken to determine the concentration of selenium in platelets and white cells, the activity of GSH-Px in red cells and platelets and the concentration of vitamin E in plasma. In addition, a 6 mm diameter sample of uninvolved skin was excised from the lateral side of the buttock to measure the concentration of selenium in skin. The skin was removed using a biopsy punch (Stiefel Laboratories) after anaesthetising the skin with 2% lignocaine.
The patients were allocated to either supplementation group I, 2, or 3 using a set of random numbers (Table I) Samples of whole blood, red cells, plasma, platelets and white cells were stored at -20°C until analysed and the activity ofGSH-Px and the concentration of vitamin E were always measured within two weeks of venesection. The white cell samples were prepared by the method described by Hinks et al." Selenium was measured using hydride generation and atomic absorption spectroscopy" and the method was adapted and validated for use with samples of skin." The activity of GSH-Px was determined using reaction rate kinetics," the concentration of vitamin E was measured by high pressure liquid chromatography" and protein by the Lowry method." The between-batch coefficient of variation for selenium measurement in whole blood and plasma was 4·8% and for platelets 6'7%; for vitamin E 3·4% and for GSH-Px activity 9·2%. The data were analysed using Student's t-test.
Results
During the study 4 patients were excluded. One taking selenium and one taking placebo had an exacerbation of their psoriasis requiring hospital admission. One taking selenium did not attend after 8 weeks and one taking placebo was excluded at week 8 after admitting to taking vitamins.
The mean concentrations of selenium in whole blood and plasma in the patients were significantly reduced compared with those of the matched controls (P < 0·00 I) but GSH-Px activity in red cells was normal ( Table 2) . The mean white cell selenium concentrations in the three groups were near the lower end of the local reference range of 1·04-3,2 pmol/10 6 cells.l" The mean plasma vitamin E concentrations were in the middle of the local reference range for Southampton (12-36 j.Lmol/L).2! No correlation was found between the PASI score and whole blood, plasma or white cell selenium concentration or red cell GSH-Px activity.
After two weeks supplementation, there was a significant increase in the mean plasma selenium concentration (P<O'OI) ( Fig. la) , platelet GSH-Px activity (P<O'OI) ( Fig. Ib) and plasma vitamin E concentration (P<0·02) (Fig. Ic) , in Groups I and 2. After four weeks supplementation, there was a significant increase in the mean platelet selenium concentration (P < 0·0 I) (Fig.  l d) and whole blood selenium concentration (P<O·OOI) (Fig. Ie) in the same groups. Neither the concentration of selenium in skin (Table 3) nor the activity of GSH-Px in red cells increased over the 12 weeks of supplementation. There was a significant rise in the white cell selenium concentration in Group I but not in Group 2 (Fig. If) . Twelve weeks after supplementation had ceased all the measurements in Groups I and 2 had returned to their pre-supplementation values. Week 0  Mean  4·3  4·33  4·84  SD  ± 1·33  ±1·5  ±1·81  No.  22  23  23 Week 12  Mean  4·3  4·55  4·31  SD  ±1·52  ±1·31  ±1·41  No. 19 21 21 There was no significant difference between the values either in Groups I or 2 and Group 3.
Neither supplementation regimen produced a significantly greater reduction in mean PASI score than did placebo, at any follow up visit, nor did the patients report that active supplementation was more effective than placebo. None of the patients in Groups I or 2 developed symptoms or signs that could be related to selenium toxicity, and measurements of haemoglobin, white cell count, platelet count and plasma urea, creatinine, alkaline phosphatase and aspartate transaminase remained unchanged.
Discussion
This study showed that supplementing patients with psoriasis for 12 weeks with 600 j.Lg of selenium-enriched yeast a day produced a significant increase in selenium concentrations in whole blood, plasma and platelets and GSH-Px activity in platelets but not in the selenium content in skin. The mean concentration of selenium in white cells rose in only one of the two groups receiving selenium supplements. It is difficult to interpret this equivocal response as it was not possible to make the measurement in about one-third of the patients both before and after supplementation. The effect of supplementation with seleniumenriched yeast on the concentration of selenium in platelets, white cells and human skin has not been recorded before. The selenium concentrations in the patients' plasma did not rise to the levels associated with clinical signs of selenium toxicity" and supplementation with selenium did not improve the patients' psoriasis. As the study would have detected a 50% reduction in the severity of the disease, the finding suggests that this form of selenium supplement is not an effective treatment for psoriasis.
Before supplementation the patients had significantly lower whole blood and plasma selenium concentrations than their healthy matched controls, thus confirming the previous finding," and their mean white cell selenium concentration was near the lower end of the local reference range." Unlike the patients with psoriasis in Sweden," red cell GSH-Px in our patients was normal. Although the concentration of selenium in our patients' whole blood was reduced, it was still at a level which would be expected to ensure maximal red cell GSH-Px activity.' The mean plasma vitamin E concentration of the patients was in the middle of the local reference range" indicating that they did not have a concomitant deficiency in vitamin E that might worsen the effects of a reduction in their selenium status."
The differing responses to supplementation of whole blood, plasma and platelets on the one hand to that of skin and white cells on the other, illustrates the problem in choosing suitable material for the measurement of selenium status in humans. The findings of this study cast doubt on the interpretation of studies that have used whole blood or plasma selenium concentrations as the sole measures of selenium status. In experimental animals the selenium content of the skin is related to selenium intake" and therefore the selenium content of the patients' skin was expected to increase during supplementation. This did not occur and may explain the lack of clinical improvement. Sodium selenite has been reported to reduce cutaneous inflammation in hairless mice!' and might prove more effective.
The increase in platelet GSH-Px activity indicates that the supplements were bioavailable. The increase in GSH-Px activity of the platelets but not the red cells suggests that a higher selenium intake is required to maximise platelet GSH-Px activity than that needed for red cells. A reduction in platelet GSH-Px activity has been reported to increase the production of the aggregating agent thrornboxane." Psoriatic platelets have an increased tendency to aggregate.v" It has been suggested that this may be responsible for the increased incidence of occlusive vascular disease found in psoriasis" since one large survey of subjects with psoriasis found a normal profile of the known risk factors for cardiovascular disease."
